Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The RAS-RAF-MEK-ERK pathway is crucial for cell growth and survival.
• Aberrant activation of this pathway drives tumor formation, with RAS and RAF mutations common in many cancers.
• Molecular target inhibitors are FDA-approved for cancer therapy, often affecting cell proliferation and metabolism.

Purpose of the Study:

• To review the development of inhibitors targeting the RAS-RAF-MEK-ERK pathway.
• To focus on inhibitors currently used in clinical cancer treatment.
• To explore potential combination therapies involving this pathway.

Main Methods:

• Literature review of inhibitors targeting the RAS-RAF-MEK-ERK pathway.
• Analysis of clinical applications and development of these inhibitors.
• Discussion of synergistic effects with other signaling pathway inhibitors.

Main Results:

• Significant progress has been made in developing inhibitors for the RAS-RAF-MEK-ERK pathway.
• Several inhibitors targeting this pathway are approved for clinical use.
• Combination strategies show promise for overcoming resistance and improving efficacy.

Conclusions:

• Inhibitors of the RAS-RAF-MEK-ERK pathway have significantly advanced cancer treatment strategies.
• Further research into combination therapies is warranted to maximize therapeutic potential.
• These targeted therapies are critical for ongoing cancer research and patient care.